Cannabis company Tilray acquires stake Medmen notes in bet on U.S. legalization. In the deal, Tilray acquired 75% of Medmen's outstanding secured convertible notes from Gotham Green Partners and 65% of its outstanding warrants.17 Aug 2021
Is MedMen making money?
Revenue 1: Net revenue across MedMen's continuing operations in California, Nevada, Illinois, Arizona and Florida was $145.1 millionfor fiscal year 2021, down 6.6% from the prior year, reflecting the impact of COVID-19, particularly during the first half of the fiscal year and in the Las Vegas and California markets.23 Sept 2021
Is TLRY a buy?
Shares of Tilray are not in a base or in buy range. So TLRY stock is not a buy right now. IBD advises investors to focus on stocks with stronger fundamentals that are moving into buy zones.2 days ago
Who is buying MedMen?
producer Tilray Inc
Is MedMen a good stock to buy now?
Is MedMen Enterprises a buy right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MedMen Enterprises in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MedMen Enterprises stock.